Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Nov 2011 - :1873-2518 [PMID:22122856]
[Sims RB]

Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
Jun 2011 - J Cancer; 2:1837-9664 [PMID:21716715]
[Sims RB]